mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Hiam Chemaitelly; Hadi M Yassine; Fatiha M Benslimane; Hebah A Al Khatib; Patrick Tang; Mohammad R Hasan; Joel A Malek; Peter Coyle; Houssein H Ayoub; Zaina Al Kanaani; Einas Al Kuwari; Andrew Jeremijenko; Anvar Hassan Kaleeckal; Ali Nizar Latif; Riyazuddin Mohammad Shaik; Hanan F Abdul Rahim; Gheyath K Nasrallah; Mohamed Ghaith Al Kuwari; Hamad Eid Al Romaihi; Mohamed H Al-Thani; Abdullatif Al Khal; Adeel A Butt; Roberto Bertollini; Laith J Abu-Raddad

doi:10.1038/s41591-021-01446-y

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Hiam Chemaitelly, Hadi M Yassine, Fatiha M Benslimane, Hebah A Al Khatib, Patrick Tang, Mohammad R Hasan, Joel A Malek, Peter Coyle, Houssein H Ayoub, Zaina Al Kanaani, Einas Al Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F Abdul Rahim, Gheyath K Nasrallah, Mohamed Ghaith Al Kuwari, Hamad Eid Al Romaihi, Mohamed H Al-ThaniAbdullatif Al Khal, Adeel A Butt, Roberto Bertollini, Laith J Abu-Raddad

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

1 Downloads (Pure)

Abstract

The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with 'wild-type' variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7-91.5%) ≥14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8-100.0%) ≥14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5-65.5%) and 96.4% after the second dose (95% CI: 91.9-98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0-88.8%) and 95.7% (95% CI: 73.4-99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose.

Original language	English
Pages (from-to)	1614–1621
Journal	Nature Medicine
Volume	27
Issue number	9
Early online date	09 Jul 2021
DOIs	https://doi.org/10.1038/s41591-021-01446-y
Publication status	Published - Sep 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41591-021-01446-yLicence: Unspecified

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
Copyright 2021 The Authors. This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms of use of the publisher.
Accepted author manuscript, 542 KBLicence: Unspecified

Cite this

Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Malek, J. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., Al Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G. K., Al Kuwari, M. G., Al Romaihi, H. E., ... Abu-Raddad, L. J. (2021). mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nature Medicine, 27(9), 1614–1621. https://doi.org/10.1038/s41591-021-01446-y

@article{04806d61a4184a508c45475fe561f8f0,

title = "mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar",

abstract = "The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with 'wild-type' variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7-91.5%) ≥14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8-100.0%) ≥14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5-65.5%) and 96.4% after the second dose (95% CI: 91.9-98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0-88.8%) and 95.7% (95% CI: 73.4-99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose. ",

author = "Hiam Chemaitelly and Yassine, {Hadi M} and Benslimane, {Fatiha M} and {Al Khatib}, {Hebah A} and Patrick Tang and Hasan, {Mohammad R} and Malek, {Joel A} and Peter Coyle and Ayoub, {Houssein H} and {Al Kanaani}, Zaina and {Al Kuwari}, Einas and Andrew Jeremijenko and Kaleeckal, {Anvar Hassan} and Latif, {Ali Nizar} and Shaik, {Riyazuddin Mohammad} and {Abdul Rahim}, {Hanan F} and Nasrallah, {Gheyath K} and {Al Kuwari}, {Mohamed Ghaith} and {Al Romaihi}, {Hamad Eid} and Al-Thani, {Mohamed H} and {Al Khal}, Abdullatif and Butt, {Adeel A} and Roberto Bertollini and Abu-Raddad, {Laith J}",

year = "2021",

month = sep,

doi = "10.1038/s41591-021-01446-y",

language = "English",

volume = "27",

pages = "1614–1621",

journal = "Nature Medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "9",

}

Chemaitelly, H, Yassine, HM, Benslimane, FM, Al Khatib, HA, Tang, P, Hasan, MR, Malek, JA, Coyle, P, Ayoub, HH, Al Kanaani, Z, Al Kuwari, E, Jeremijenko, A, Kaleeckal, AH, Latif, AN, Shaik, RM, Abdul Rahim, HF, Nasrallah, GK, Al Kuwari, MG, Al Romaihi, HE, Al-Thani, MH, Al Khal, A, Butt, AA, Bertollini, R & Abu-Raddad, LJ 2021, 'mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar', Nature Medicine, vol. 27, no. 9, pp. 1614–1621. https://doi.org/10.1038/s41591-021-01446-y

TY - JOUR

T1 - mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

AU - Chemaitelly, Hiam

AU - Yassine, Hadi M

AU - Benslimane, Fatiha M

AU - Al Khatib, Hebah A

AU - Tang, Patrick

AU - Hasan, Mohammad R

AU - Malek, Joel A

AU - Coyle, Peter

AU - Ayoub, Houssein H

AU - Al Kanaani, Zaina

AU - Al Kuwari, Einas

AU - Jeremijenko, Andrew

AU - Kaleeckal, Anvar Hassan

AU - Latif, Ali Nizar

AU - Shaik, Riyazuddin Mohammad

AU - Abdul Rahim, Hanan F

AU - Nasrallah, Gheyath K

AU - Al Kuwari, Mohamed Ghaith

AU - Al Romaihi, Hamad Eid

AU - Al-Thani, Mohamed H

AU - Al Khal, Abdullatif

AU - Butt, Adeel A

AU - Bertollini, Roberto

AU - Abu-Raddad, Laith J

PY - 2021/9

Y1 - 2021/9

N2 - The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with 'wild-type' variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7-91.5%) ≥14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8-100.0%) ≥14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5-65.5%) and 96.4% after the second dose (95% CI: 91.9-98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0-88.8%) and 95.7% (95% CI: 73.4-99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose.

AB - The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with 'wild-type' variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7-91.5%) ≥14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8-100.0%) ≥14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5-65.5%) and 96.4% after the second dose (95% CI: 91.9-98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0-88.8%) and 95.7% (95% CI: 73.4-99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose.

U2 - 10.1038/s41591-021-01446-y

DO - 10.1038/s41591-021-01446-y

M3 - Article

C2 - 34244681

VL - 27

SP - 1614

EP - 1621

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 9

ER -

mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this